http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-084044-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5e258f75ecc74c6ee8717365c646a95 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7064 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19786d547d0781973fbf090ecbd3e20d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bd1e4aa80e538320dd50cd87b2752a2 |
| publicationDate | 2013-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-084044-A1 |
| titleOfInvention | 2’-ESPIRO-NUCLEOSID COMPOUNDS |
| abstract | 2′-spiro-nucleosides and their derivatives useful for treating a subject infected with hepatitis C virus or dengue virus are disclosed herein. A process for preparing the compound is also disclosed. Claim 1: A compound or its stereoisomer or its salt or metabolite or its deuteride represented by the formula (1), wherein: I) R1 is selected from a) hydrogen, b) -P (O) (OH) 2, c) -P (O) (O (CH2) 1-3OC (O) O (alkyl) 2, d) -P (O) (O (CH2) 1-3OC (O) (alkyl)) 2, e) -P (O) (O (CH2) 1-3SC (O) (alkyl)) 2, f) -P (O) (O (CH2) 1-3OCH2 (aryl )) 2, g) -P (O) (O (CH2) 1-3SCH2 (aryl)) 2, h) -P * (O) (OR1a) (NHCHR1bC (O) OR1c), where R1a is i) hydrogen , ii) alkyl, iii) cycloalkyl or iv) aryl, R1b is i) hydrogen, ii) C1-6 alkyl, iii) cycloalkyl, iv) alkaryl ov) alk (heteroaryl) and R1c is i) hydrogen, ii) alkyl, iii) cycloalkyl or iv) alkaryl, i) -P * (O) (NH (alkaryl) (O (CH2) 1-3SC (O) (alkyl)), j) a 1,3,2-dioxafosfinan-2- oxide, k) a 4H-benzo [d] [1,3,2] dioxafosfinin-2-oxide, l) -P * (O) (OR1c) ~, when Y is -O ~, where R1c is defined above , m) -P (O) (OH) -OP (O) (OH) 2, n) -P (O) (OH) -OP (O) (OH) -OP (O) (OH) 2, or ) an acyl, p) an alkyl len C1-6-oxy-acyl, and q) a -C (O) -O-alkyl; II) R2 is selected from a) hydrogen, b) fluoro, c) azido, d) cyano, e) a C1-6 alkyl, f) a vinyl and g) an ethynyl; III) R3 is selected from a) hydrogen, b) methyl, and c) cyano; IV) Y is selected from a) hydrogen, b) fluoro, c) -OH, d) -O ~, when R1 is -P (O) (OR1c) ~, where R1c is defined previously, e) -O (acyl), f) -O (C1-6 alkylene-oxy-acyl), g) -OC (O) -O-alkyl, h) -NH2, i) -NH (acyl), j) -NH-C (O) -O-alkyl, and k) azido; V) X is selected from a) -O-, b) -S-, c) -NH-, d) -CH2-, e)> C = CH2, and f) -NH-C (O) -O- I rent; VI) the Z ring is a four or five member ring selected from among radicals represented by the structures of formulas (a) - (o), where * represents the point of attachment with the 2 'carbon and where a) A is selected from i) -O-, ii) -S-, iii) -S (O) -, iv) -S (O) 2-, and v) -NH-, b) D is selected from i) -O -, ii) -S- except for the rings of formula (i) and (j), iii) -S (O) - except for the rings of formula (i) and (j), iv) -S (O) 2- except for the rings of formula (i) and (j), and v) -NH- except for the rings of formula (i) and (j), vi) -N-, vii) a methylene except for the rings of formula (i) and (j), viii) a methine, and ix) a vinylidene except for the rings of formula (i) and (j), c) R4, R4 ', R5, R5', R6, R7, R8 , R8 ', R9 and R9' are independently selected from i) hydrogen, ii) halo, iii) C1-6 alkyl, iv) hydroxy, v) alkoxy, vi) cycloalkoxy, vii) -O (acyl ), viii) -O (C1-6-oxyacyl alkylene), ix) -OC (O) -O-alkyl, x) alkyl C1-6-oxy (alkyl), xi) alkenyl, xii) ethynyl, xiii) -NH2, xiv) -NH (alkyl), xv) -NH (cycloalkyl), xvi) heterocyclyl, xvii) aryl, and xviii) heteroaryl; and VII) B is selected from the structures of formula (B1), (B2) and (B3), where for the structure of formula (B1), n is 0 or 1, a) when n is 0, - - - - - is a double bond and R10 is selected from i) -NH2, ii) -NH (alkyl), iii) -NH (acyl), iv) -NH-C (O) -O-alkyl, v) - cycloheteroalkyl, vi) -heteroaryl, vii) -O (alkyl), viii) -O (acyl), ix) -O (C1-6 alkylene-oxyacyl) and x) -OC (O) -O-alkyl, ob) when n is 1, - - - - - is a simple bond and R10 is selected from i) = O, ii) = NH, and iii) = N (alkyl), and c) regardless of the value of n, R11 and R12 are independently selected from i) hydrogen, ii) halo, iii) cyano, iv) C1-6 alkyl, v) C2-5 alkenyl and vi) C2-5 alkynyl; where for the structure of formula (B2), a) R13 is selected from i) hydrogen, ii) halo, iii) cyano, iv) -C (O) NH2, v) C1-6 alkyl, vi) vinyl, and vii) ethynyl; where for the structure of formula (B3), m is 0 or 1 and - - - - - is a single or double bond a) when m is 0, - - - - - is a double bond and R16 and R17 are selected, independently, from i) hydrogen, ii) -NH2, iii) -NH (alkyl), iv) -NH (acyl), iv) -NH-C (O) -O-alkyl, v) -cycloheteroalkyl, vi) -O (alkyl), vii) -O (acyl), viii) -O (C1-6-oxyacyl alkylene), ix) -OC (O) -O-alkyl, and x) -S (alkyl), ob ) when m is 1, - - - - - is a single bond, b1) R16 is selected from i) = O, ii) = NH and iii) = N (alkyl) and b2) R17 is selected from i) -NH2, ii) -NH (alkyl), iii) -NH (acyl), iv) -NH-C (O) -O-alkyl, and v) -cycloheteroalkyl, c) regardless of the value of m, each binding pair , W1- - - - -W2, W2- - - - -C, C- - - - -W4, W4- - - - -W3 and W3- - - - -W1, contained in the five-member ring comprises a single or double bond and i) W1 is O, S, N or CR14, ii) W2 is N or CR15, iii) W3 is C or N, and iv) W4 is C or N and where R14 and R15, if present They are independently selected from i) hydrogen, ii) halo, iii) cyano, iv) -C (O) NH2, iv) C1-6 alkyl, vii) vinyl, and viii) ethynyl. |
| priorityDate | 2010-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.